Citation

Billa R, Tigges C, Vijayakumar N, Radke J, Pedati C, Weiner R, McCabe D. J. Med. Toxicol. 2020; ePub(ePub): ePub.

Affiliation

Department of Emergency Medicine, University of Iowa, Iowa City, IA, USA. daniel-j-mccabe@uiowa.edu.

Copyright

(Copyright © 2020, Holtzbrinck Springer Nature Publishing Group)

DOI

10.1007/s13181-020-00765-9

PMID

32193828

Abstract

INTRODUCTION: E-cigarette, or vaping, product use associated lung injury (EVALI) has become a recent concern among public health officials. Factors that contribute to the concern include an increasing number of cases over time, the severity of the illness, and an unknown understanding of the pathophysiology and etiology of the illness. CASE SERIES: We cared for three adolescent patients with acute respiratory failure secondary to EVALI. All three patients were treated with high-dose steroids in addition to antimicrobials, which resulted in clinical improvement and resolution of their respiratory failure. Pulmonary function testing was performed on these previously healthy patients both acutely and subacutely. Additionally, we report the results from the laboratory analysis of one vaping device fluid which revealed previously unpublished components within these products.

DISCUSSION: EVALI is a recent public health concern without a known etiology which can cause life-threatening lung injury in patients without prior lung pathology. We hope these cases will highlight the importance of return precautions in adolescents with vague respiratory symptoms and provide a cautionary tale to providers while they counsel patients regarding the use of these products.

Language: en

Keywords

ARDS; EVALI; Lung injury; Vaping